Key Insights Protagonist Therapeutics to hold its Annual General Meeting on 20th of June Salary of US$655.2k is part of...
Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Patients receiving rusfertide ...
Protagonist Therapeutics (NASDAQ:PTGX) has had a great run on the share market with its stock up by a significant 24...